Skip to main content
SpringerLink
Log in

Molecular Targeting in Upper Gastrointestinal Malignancies

  • Chapter
Molecular Targeting in Oncology

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 1435 Accesses

Summary

Tumors of the upper gastrointestinal tract (GI) are not common but represent a significant clinical challenge. Treatment of locally advanced and metastatic tumors of the upper GI tract, liver and pancreas has met with limited success using standard cytotoxic agents. The development of agents that block signal transduction pathways, cell cycle proteins, proteosomal degredation, angiogenesis and immunologic-based approaches are being tested in this group of tumors. These studies have better defined the toxicity profiles of these agents but have resulted in limited successful clinical responses. The pre-clinical and preliminary clinical trial results will be reviewed and some of the problems with targeted therapy in the upper GI tract cancer population will be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jemal, A., R.C. Tiwari, T. Murray, A. Ghafoor, A. Samuels, E. Ward, E.J. Feuer, and M.J. Thun, Cancer statistics. CA Cancer J Clin, 2004 54(1): p. 8–29.

    Google Scholar 

  2. Doi, T., W. Koizumi, S. Siena, et al., Efficacy, tolerability and pharmacokinetics of gefitinib (ZD 1839) in pretreated patients with metastatic gastric cancer. Proc ASCO, 2003, abstract 103.

    Google Scholar 

  3. Rojo, F., J. Tabernero, and E. Van Cutsem, Pharmacodynamic studies of tumor biopsy specimens from patients undergoing treatment with gefitinib. Proc ASCO, 2003, abstract 764.

    Google Scholar 

  4. Yasui, W., N. Oue, H. Kuniyasu, et al., Molecular diagnosis of gastric cancer: present and future. Gastric Cancer, 2001 4: p. 113–21.

    Google Scholar 

  5. Yasui, W., H. Yokozoki, F. Shimamato, et al., Molecular-pathologic diagnosis of gastrointestinal tissues and its contribution to cancer histopathology. Pathol Int, 1999 49: p. 763–74.

    Google Scholar 

  6. Xaingming, C., S. Natsugoe, S. Takao, et al., The cooperative role of p27 and cyclin E in the prognosis of advanced gastric cancer. Cancer, 2000 89: p. 1214–9.

    Google Scholar 

  7. Mosolits, S., G. Ullenhag, and H. Mellstedt, Therapeutic vaccination in patients with gastrointestinal malignancies: a review of immunological and clinical results. Ann Oncol, 2005 16: p. 847–62.

    Article  PubMed  CAS  Google Scholar 

  8. Zhang, H., J. Wu, L. Meng, and C. Shou, Expression of vascular endothelial growth factor and its receptors KDR and flt-1 in gastric cancer cells. World J Gastroenterol, 2002 8: p.994–8.

    PubMed  CAS  Google Scholar 

  9. Mitani, Y., N. Oue, Y. Hamai, et al., H3 acetylation is associated with reduced p21 WAF1/CIP1 expression in gastric carcinoma. J Pathol, 2005 205: p.65–73.

    Article  PubMed  CAS  Google Scholar 

  10. Suzuki, T., H. Kuniyasu, K. Hayashi, et al., Effect of trichostatin A on cell growth and expression cell-cycle and apoptosis-related in human gastric and oral carcinoma cell lines. Int J Cancer, 2000 88: p. 992–7.

    Article  PubMed  CAS  Google Scholar 

  11. Hippo, Y., H. Taniguchi, S. Tsutsumi, et al., Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res, 2002 62: p. 233–40.

    PubMed  CAS  Google Scholar 

  12. Hasegawa, S., Y. Furukawa, M. Li, et al., Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23,040 genes. Cancer Res, 2002 62: p. 7012–7.

    PubMed  CAS  Google Scholar 

  13. Yasui, W., N. Oue, N. Ito, et al., Search through new biomarkers of gastric cancer through serial analysis of gene expression and its clinical implications. Cancer Sci, 2004 95: p. 385–92.

    Article  PubMed  CAS  Google Scholar 

  14. Yoshida, K., K. Tanabe, H. Ueno, K. Ohta, J. Hihara, T. Toge, and M. Nishiyama, Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study. Gastric Cancer, 2003 6 Suppl 1: p. 82–9.

    Article  PubMed  Google Scholar 

  15. Scartozzi, M., E. Galizia, F. Freddari, R. Berardi, R. Cellerino, and S. Cascinu, Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. Cancer Treat Rev, 2004 30(5): p. 451–9.

    Article  PubMed  CAS  Google Scholar 

  16. Takehana, T., K. Kunitomo, K. Kono, F. Kitahara, H. Iizuka, Y. Matsumoto, M.A. Fujino, and A. Ooi, Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer, 2002 98(6): p. 833–7.

    Article  PubMed  CAS  Google Scholar 

  17. Gong, S.J., C.J. Jin, S.Y. Rha, and H.C. Chung, Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Lett, 2004 214(2): p. 215–24.

    Article  PubMed  CAS  Google Scholar 

  18. Takehana, T., K. Kunitomo, S. Suzuki, K. Kono, H. Fujii, Y. Matsumoto, and A. Ooi, Expression of epidermal growth factor receptor in gastric carcinomas. Clin Gastroenterol Hepatol, 2003. 1(6): p. 438–45.

    Article  PubMed  CAS  Google Scholar 

  19. Choudhury, A., J. Charo, S.K. Parapuram, R.C. Hunt, D.M. Hunt, B. Seliger, and R. Kiessling, Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer, 2004 108(1): p.71–7.

    Article  PubMed  CAS  Google Scholar 

  20. Tanner, M., M. Hollmen, T.T. Junttila, A.I. Kapanen, S. Tommola, Y. Soini, H. Helin, J. Salo, H. Joensuu, E. Sihvo, K. Elenius, and J. Isola, Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol, 2005 16(2): p.273–8.

    Article  PubMed  CAS  Google Scholar 

  21. Kishida, O., Y. Miyazaki, Y. Murayama, M. Ogasa, T. Miyazaki, T. Yamamoto, K. Watabe, S. Tsutsui, T. Kiyohara, I. Shimomura, and Y. Shinomura, Gefitinib (“Iressa”, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells. Cancer Chemother Pharmacol, 2005 55(4): p. 393–403.

    Article  PubMed  CAS  Google Scholar 

  22. Park, J.K., S.H. Lee, J.H. Kang, K. Nishio, N. Saijo, and H.J. Kuh, Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells. Anticancer Drugs, 2004. 15(8): p.809–18.

    Article  PubMed  CAS  Google Scholar 

  23. Vanhoefer, U., M. Tewes, F. Rojo, O. Dirsch, N. Schleucher, O. Rosen, J. Tillner, A. Kovar, A.H. Braun, T. Trarbach, S. Seeber, A. Harstrick, and J. Baselga, Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol, 2004 22(1): p.175–84.

    PubMed  CAS  Google Scholar 

  24. Trarbach, T., T. Beyer, N. Schleucher, et al., A randomized phase I study of the humanized anti-epidermal growth factor monoclonal antibody EMD 72000 in subjects with advanced gastrointestinal cancers. J Clin Oncol, 2004 22(14S): p.3018.

    Google Scholar 

  25. Schwartz, G.K., D. Ilson, L. Saltz, E. O’Reilly, W. Tong, P. Maslak, J. Werner, P. Perkins, M. Stoltz, and D. Kelsen, Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol, 2001 19(7): p.1985–92.

    PubMed  CAS  Google Scholar 

  26. Thomas, J.P., K.D. Tutsch, J.F. Cleary, H.H. Bailey, R. Arzoomanian, D. Alberti, K. Simon, C. Feierabend, K. Binger, R. Marnocha, A. Dresen, and G. Wilding, Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol, 2002 50(6): p.465–72.

    Article  PubMed  CAS  Google Scholar 

  27. Bruns, C.J., M.T. Harbison, D.W. Davis, C.A. Portera, R. Tsan, D.J. McConkey, D.B. Evans, J.L. Abbruzzese, D.J. Hicklin, and R. Radinsky, Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res, 2000 6(5): p.1936–48.

    PubMed  CAS  Google Scholar 

  28. Ng, S.S., M.S. Tsao, T. Nicklee, and D.W. Hedley, Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther, 2002 1(10): p.777–83.

    PubMed  CAS  Google Scholar 

  29. Shah, S.A., M.W. Potter, T.P. McDade, R. Ricciardi, R.A. Perugini, P.J. Elliott, J. Adams, and M.P. Callery, 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem, 2001 82(1): p.110–22.

    Article  PubMed  CAS  Google Scholar 

  30. Fahy, B.N., M.G. Schlieman, S. Virudachalam, and R.J. Bold, Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer. J Surg Res, 2003 113(1): p.88–95.

    Article  PubMed  CAS  Google Scholar 

  31. Fujioka, S., G.M. Sclabas, C. Schmidt, W.A. Frederick, Q.G. Dong, J.L. Abbruzzese, D.B. Evans, C. Baker, and P.J. Chiao, Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res, 2003 9(1): p. 346–54.

    PubMed  CAS  Google Scholar 

  32. Bold, R.J., S. Virudachalam, and D.J. McConkey, Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res, 2001 100(1): p.11–7.

    Article  PubMed  CAS  Google Scholar 

  33. Guha, S., K. Kisfalvi, G. Eibl, et al., [D Arg 1, DTrp 5,7,9, Leu 11]SP: a novel, potent inhibitor of mitogenic signaling and growth in vitro and in vivo in human pancreatic cancer. Gastrointestinal Cancers Symposium, 2004.

    Google Scholar 

  34. Baerman, K., L. Caskey, F. Dasi, et al., EGFR/HER2 targeted therapy inhibits growth of pancreatic cancer cells. Gastrointestinal Cancers Symposium, 2005.

    Google Scholar 

  35. Bloom, D., W. Cance, E. Kurenova, et al., Dual inhibition of FAK and IGF-IR increases apoptosis through akt down-regulation in human pancreatic adenocarcinoma cells. Gastrointestinal Cancers Symposium, 2005.

    Google Scholar 

  36. Fahy, B.N., M.G. Schlieman, M.M. Mortenson, S. Virudachalam, and R.J. Bold, Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol, 2005 56(1): p.46–54.

    Article  PubMed  CAS  Google Scholar 

  37. Bramhall, S.R., A. Rosemurgy, P.D. Brown, C. Bowry, and J.A. Buckels, Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol, 2001 19(15): p.3447–55.

    PubMed  CAS  Google Scholar 

  38. Kindler, H.L., G. Friberg, W. Stadler, et al. Bevacizumab plus gemcitabine is an active combination in patients with advanced pancreatic cancer: interim results of an ongoing phase II trial from the Univ of Chicago Phase II consortium. Gastrointestinal Cancers Symposium, 2004.

    Google Scholar 

  39. Kindler, H.L., M. Lobell, D. Smith, et al. SDX-102: a targeted therapy for previously treated, MTAP-deficient pancreatic cancer and gastrointestinal stromal tumors. Gastrointestinal Cancers Symposium, 2004.

    Google Scholar 

  40. Brett, B.T., S.C. Smith, C.V. Bouvier, D. Michaeli, D. Hochhauser, B.R. Davidson, T.R. Kurzawinski, A.F. Watkinson, N. Van Someren, R.E. Pounder, and M.E. Caplin, Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol, 2002 20(20): p.4225–31.

    Article  PubMed  CAS  Google Scholar 

  41. Shapiro, J., J. Marshall, P. Karasek, et al., G17DT + gemcitabine versus placebo + gemcitabine in untreated subjects with locally advanced, recurrent or metastatic adenocarcinoma of the pancreas: results of a randomized, double-blind, multinational, multicenter study. ASCO Ann Mtg-41st Ann Mtg, 2005. Orlando, Fl.

    Google Scholar 

  42. Cohen, S.J., L. Ho, S. Ranganathan, J.L. Abbruzzese, R.K. Alpaugh, M. Beard, N.L. Lewis, S. McLaughlin, A. Rogatko, J.J. Perez-Ruixo, A.M. Thistle, T. Verhaeghe, H. Wang, L.M. Weiner, J.J. Wright, G.R. Hudes, and N.J. Meropol, Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol, 2003 21(7): p.1301–6.

    Google Scholar 

  43. Graeven, U., I. Vogel, B. Killings, et al., Phase I study of humanized IgG1 anti-epidermal growth factor receptor monoclonal antibody EMD 72000 plus gemcitabine in advanced pancreatic cancer. J Clin Oncol, 2004 22(14S): p.3061.

    Google Scholar 

  44. Moore, M.J., J. Hamm, J. Dancey, P.D. Eisenberg, M. Dagenais, A. Fields, K. Hagan, B. Greenberg, B. Colwell, B. Zee, D. Tu, J. Ottaway, R. Humphrey, and L. Seymour, Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12–9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 2003 21(17): p.3296–302.

    Article  PubMed  CAS  Google Scholar 

  45. Hecht, J.R., R. Bedford, J.L. Abbruzzese, S. Lahoti, T.R. Reid, R.M. Soetikno, D.H. Kirn, and S.M. Freeman, A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res, 2003 9(2): p.555–61.

    PubMed  CAS  Google Scholar 

  46. Hanna, N., T. Chung, J. Hecht, et al., Safety and efficacy of TNFerade in unresectable locally advanced pancreatic cancer: results of the first two cohorts of a dose escalating study. Gastrointestinal Cancers Symposium, 2004.

    Google Scholar 

  47. Aklilu, M., H.L. Kindler, S. Nattam, et al., A phase II study of arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine. Gastrointestinal Cancers Symposium, 2004.

    Google Scholar 

  48. Kortmansky, J., E. O’Reilly, B. Minsky, et al. A phase I trial of erlotinib, gemcitabine and radiation for patients with locally advanced, unresectable pancreatic cancer. Gastrointestinal Cancers Symposium, 2005.

    Google Scholar 

  49. Crane, C., L. Ellis, J. Abbruzzese, et al., Phase I trial of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic adenocarcinoma. ASCO Ann Mtg-41st Ann Mtg, 2005, Orlando, FL.

    Google Scholar 

  50. Bekaii-Saab, T., T. Sawada, N. Williams, et al. Intragenic EGFR and EGFR2 mutations in hepatobiliary tumors and potential role in predicting response to agents that target EGFR. ASCO Ann Mtg-41st Ann Mtg, 2005. Orlando, Fl.

    Google Scholar 

  51. Treiber, G., T. Wex, and P. Malfertheiner, Plasma PDGF and VEGF as sensitive biomarkers for monitoring of angiogenesis in hepatocellular cancer patients. ASCO Ann Mtg-41st Ann Mtg, 2005. Orlando, FL.

    Google Scholar 

  52. Schwartz, J.D., FLM. Schwartz, FLJ. Goldman, et al., Bevacizumab in hepatocellular carcinoma for patients without metastasis and without invasion of the portal vein. Gastrointestinal Cancers Symposium, 2005.

    Google Scholar 

  53. Britten, C., R. Finn, A. Gomes, et al., A pilot study of IV bevacizumab in hepatocellular cancer patients undergoing chemoembolization. ASCO Ann Mtg-41st Ann Mtg, 2005. Orlando, FL.

    Google Scholar 

  54. Zhu, A., D. Sahani, A. Norden-Zfoni, et al. A phase II study of gemcitabine, oxaliplatin in combination with bevacizumab in patients with hepatocellular carcinoma. Gastrointestinal Cancers Symposium, 2005.

    Google Scholar 

  55. Thomas, M., A. Dutta, T. Brown, et al., A phase II open label study of OSI-774 in unresectable hepatocellular carcinoma. ASCO Ann Mtg-41st Ann Mtg, 2005. Orlando, FL.

    Google Scholar 

  56. Philip, P., M. Mahoney, J. Thomas, et al. Phase II trial of OSI-774 in patients with hepatocellular and biliary cancer. Gastrointestinal Cancers Symposium, 2004.

    Google Scholar 

  57. Lin, A., G. Fisher, S. So, et al., A phase II study of imatinib mesylate in patients with unresectable hepatocellular carcinoma. ASCO Ann Mtg-41st Ann Mtg, 2005. Orlando, FL.

    Google Scholar 

  58. Llovet, J., Ricci, S., Mazzaferro, V., et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol ASCO Proc, 2007 25: pLBA1

    Google Scholar 

  59. Mendelsohn, J., D. Shin, N. Donato, et al., A phase I study of chimerized anti-epidermal growth factor recombinant monoclonal antibody in combination with cisplatin in patients with recurrent head and neck squamous cell carcinoma. 35th Ann Mtg of the Am Soc Clin Oncol, 1999.

    Google Scholar 

  60. Baselga, J., D. Pfister, M. Cooper, et al., Phase I studies of anti-epidermal growth factor receptor chimeric C225 alone and in combination with cisplatin. J Clin Oncol, 2000 18: p. 904–14.

    PubMed  CAS  Google Scholar 

  61. Kimyai-Asadi, A. and M.H. Jih, Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol, 2002 138(1): p.129–31.

    Article  PubMed  Google Scholar 

  62. Murillas, R., F. Larcher, and F. Conti, Expression of a dominant vnegative mutant epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J, 1995, 14: p.5216–23.

    PubMed  CAS  Google Scholar 

  63. Hansen, L., N. Alexander, M. Hogan, et al., Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development. Am J Pathol, 1997, 160: p.1969–75.

    Google Scholar 

  64. Shah, M., D. Ilson, and D. Kelson, Thromoembolic events in gastric cancer: high incidence in patients receiving irinotecan- or bevacizumab-based therapy. J Clin Oncol, 2005 23: p.2574–6.

    Article  PubMed  Google Scholar 

  65. Moore, M.J., D. Goldstein, J. Hamm, et al., Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. ASCO Ann Mtg-41st Ann Mtg, 2005. Orlando, FL.

    Google Scholar 

Download references

Authors
  1. Scott Wadler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Surgical Oncology, Columbia University, New York, NY

    Howard L. Kaufman

  2. Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College Cornell University, New York, NY

    Scott Wadler

  3. Boston University Medical Campus Boston University School of Medicine, Boston, MA

    Karen Antman

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press

About this chapter

Cite this chapter

Wadler, S. (2008). Molecular Targeting in Upper Gastrointestinal Malignancies. In: Kaufman, H.L., Wadler, S., Antman, K. (eds) Molecular Targeting in Oncology. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-337-0_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-337-0_6

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-577-4

  • Online ISBN: 978-1-59745-337-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation